Recent clinical analysis reveals a persistent gap in the standard of care for patients with Merkel cell carcinoma (MCC), as the utilization of adjuvant radiation therapy has failed to increase for localized disease presentations. While overall usage of radiation as a follow-up treatment for this rare, aggressive form of skin cancer has seen a marginal uptick in recent years, patients with localized tumors—who stand to benefit significantly from local control—are not receiving this intervention at higher rates, according to data published in JAMA Dermatology.
Merkel cell carcinoma is a rare neuroendocrine cancer of the skin, characterized by high rates of recurrence and potential for rapid metastasis. For clinicians, the challenge lies in balancing the aggressive nature of the disease with appropriate therapeutic escalation. The recent findings highlight a discrepancy between current clinical guidelines, which often favor adjuvant radiation for high-risk localized cases, and real-world practice patterns observed across oncology centers.
Radiation Utilization Patterns in Clinical Practice
The study, which examined longitudinal data to track treatment delivery, indicates that while adjuvant radiotherapy (ART) use for MCC has trended upward on a population-wide scale, this growth is primarily driven by cases involving more advanced stages of the disease. In contrast, the cohort of patients diagnosed with localized Merkel cell carcinoma has not experienced a corresponding rise in radiation access. According to the National Comprehensive Cancer Network (NCCN) guidelines, adjuvant radiation is frequently recommended for patients with localized MCC to reduce the risk of local recurrence, particularly in instances where surgical margins are narrow or the primary tumor site poses a high risk for regional spread.
Researchers suggest that several factors may contribute to this stagnation. Clinical decision-making for localized MCC involves complex multidisciplinary discussions between dermatologic surgeons, radiation oncologists, and medical oncologists. In many instances, the decision to forego adjuvant radiation centers on the patient’s overall health, the specific anatomical site of the tumor, and the potential for long-term side effects related to radiation exposure in younger or healthier patients.
Multidisciplinary Care and Treatment Outcomes
Effective management of Merkel cell carcinoma requires a coordinated approach to care, as defined by the National Cancer Institute. Because MCC is highly immunogenic and prone to regional lymph node involvement, the timing and necessity of radiation therapy are often debated. The failure of ART usage rates to climb in localized disease cases may reflect an ongoing effort by clinicians to minimize overtreatment in patients who have achieved clear surgical margins through wide local excision or Mohs micrographic surgery.
However, the persistence of lower radiation rates in the localized setting raises questions regarding the consistency of care. Some oncologists argue that given the high local recurrence rate of MCC—which can exceed 25% to 30% in some cohorts—adjuvant radiation should be considered more routinely. The lack of increase in utilization suggests that standardized protocols are either being interpreted conservatively or that infrastructure barriers—such as patient access to specialized radiation centers—continue to influence treatment delivery patterns.
Implications for Future Research and Patient Care
For patients and their families, understanding the role of adjuvant therapy is a critical component of the treatment journey. As research continues to evolve, the focus is shifting toward identifying which patients with localized disease derive the most benefit from radiation versus those who can safely be monitored through clinical surveillance. Current evidence, as noted by the American Academy of Dermatology, emphasizes that staging accuracy—often involving sentinel lymph node biopsy—is the primary driver for determining whether additional local therapy is required.
The medical community is now looking toward prospective studies to clarify whether the current stagnation in ART use for localized MCC is a result of intentional de-escalation strategies or an unmet clinical need. Future updates to clinical practice guidelines are expected to reflect these findings, potentially providing clearer benchmarks for when radiation therapy should be considered a standard component of care rather than an optional adjunct.
As the landscape of skin cancer treatment shifts toward more personalized, genomic-based approaches, the integration of traditional modalities like radiotherapy remains vital. Patients diagnosed with Merkel cell carcinoma are encouraged to consult with a multidisciplinary tumor board to discuss whether adjuvant radiation is appropriate for their specific tumor profile and surgical outcomes.
The next scheduled review of clinical guidelines by major oncology organizations will likely incorporate these utilization trends to determine if further education is necessary for community-based practitioners. We invite our readers to share their experiences with care coordination or ask questions regarding current treatment standards in the comments section below.